Joshua E. Meyer, MD, Joins Fox Chase's Department of Radiation Oncology

PHILADELPHIA (August 12, 2010) – Joshua E. Meyer, MD, has joined Fox Chase Cancer Center’s Department of Radiation Oncology. He specializes in treating patients with gastrointestinal cancers, including cancers of the pancreas, liver, esophagus, stomach, small intestine, colon, rectum, and anus. In addition, he treats patients with lung and brain tumors.

Meyer’s expertise includes using stereotactic radiation to deliver short courses of radiation with the highest accuracy, minimizing the risk of side effects to patients.


“I am excited to be joining Fox Chase’s extremely well-respected radiation oncology department,” Meyer says.  “Expert physicians, cutting-edge technology, and a world-class medical physics team all distinguish it as a leader in the field.”

Meyer’s clinical research has focused primarily on pancreatic cancer, including the delivery of radiation therapy prior to surgery. He also has presented and published research pertaining to other areas, including rectal and anal cancers.

“There are very few of these diseases that physicians working in individual specialties are curing by themselves,” he notes. “I look forward to bringing new energy and innovative ideas to Fox Chase’s wonderful multidisciplinary team. Through effective collaboration among radiation oncology, medical oncology, and surgical oncology, Fox Chase gives patients the best care and the most promising opportunities.”

Meyer comes to Fox Chase after completing his residency in radiation oncology at the Stich Radiation Center at Weill Cornell Medical Center and the Arnold Center for Radiation Oncology at New York Hospital Queens, serving as chief resident in his final year. He is a reviewer for Gastrointestinal Cancer Researchand maintains membership in a number of professional organizations, including the American Society of Clinical Oncology, American College of Radiology, and American Society for Therapeutic Radiology and Oncology. Among his honors, Meyer was selected as a clinical fellow at the ASCO/AACR Workshop on Methods in Clinical Cancer Research in 2009.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Resize Text